Vein Guardian Introduces Patented Passive Magnetic Concept for Vein Stabilization
virginir.com/10335507

CHICAGO - Virginir -- Axis International Marketing is introducing Vein Guardian, a patented passive magnetic vein stabilizer concept designed to help address challenges associated with vein movement during injections and vascular access procedures.

Vein Guardian incorporates two opposing C-arc magnets positioned along either side of a target vein. The same-polarity magnets are intended to create a repulsive magnetic field that helps stabilize the vein while maintaining an open center for visibility and needle access.

The invention is designed to operate without batteries, charging, or external power. Its adjustable straps and reusable configuration are intended to provide a practical, compact solution for a variety of potential healthcare applications.

Designed for Home and Clinical Applications

More on virginir.com

• Brian G. Miller Co., LLC Receives Tier 1 Ranking in the 2027 Edition of Best Law Firms®
• The Villari Firm, PLLC Named to the 2027 Edition of Best Law Firms
• Bacchus Wine & Spirits and Michelin Guide–Recommended Ethel's Fancy to Host Exclusive LOUIS XIII Limited Edition Diwali Decanter Celebration
• Arizona Pest Control Surpasses $200,000 in Contributions to Southern Arizona High School Sports and Education Programs
• ZenaTech (NAS DAQ: ZENA) $1 Million in New Utility Contracts- Potential $2.5 Million Follow-On Opportunity Puts Its Drone Business in the Spotlight!

As healthcare delivery continues to expand beyond traditional clinical environments, medical device developers are exploring technologies that may support greater patient independence and simplify certain procedures.

Vein Guardian is intended for potential applications involving home self-injection, hospital and clinical IV access, and blood collection in laboratory settings.

The invention's open-center design is intended to allow healthcare professionals and appropriately trained users to locate and access the target vein without removing the device.

A Growing Healthcare Market

According to Mordor Intelligence, the global injectable drug delivery devices market is projected to grow from approximately $810 billion in 2026 to $1.20 trillion by 2031. This broader market includes a wide range of injection technologies and reflects growing interest in home-based healthcare and self-administration.

Vein Guardian represents a proposed complementary approach to vein stabilization within this evolving healthcare environment.

More on virginir.com

• New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
• Genuine Hospitality, LLC Selected to Operate Holiday Inn Express & Suites Jacksonville – Town Center
• Shiokly Launches Online Marketplace to Help Singapore Home-Based Businesses Sell More, With First Product Listed Free
• Freight Broker 911 and Milton Collier Introduce "What's The 911?"—A New Podcast Built on Real Talk, Real Freight, and Real Opportunity
• PropAccount.com Launches PropWallet, Turning Prop Firm Payouts Into Repeat Sales

Licensing Opportunity

Vein Guardian is available for licensing consideration by medical device manufacturers, healthcare product companies, and organizations interested in developing innovative vascular access technologies.

Interested parties are encouraged to explore the invention and its potential commercial applications.

To view the Vein Guardian marketing video and discover additional patented inventions, visit:

https://123axis.com/videos/

About Axis International Marketing

Axis International Marketing works with inventors to introduce patented products and innovative concepts to prospective manufacturers, buyers, and licensing partners. Through marketing presentations, product videos, and commercial outreach, Axis helps connect inventions with potential opportunities for commercialization.

Vein Guardian is presented as a patented concept. Product illustrations are concept visualizations, and the device's clinical performance, safety, and regulatory status have not been independently established in this release.